Highfields Capital Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Highfields Capital Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-154,300	Closed	-$7.08M	–	93
2015 Q2	$7.08M	Sell	154,300 -1,245,700	-89%	-$59.1M	0.06%	71
2015 Q1	$65.6M	Hold	1,400,000	–	–	0.59%	31
2014 Q4	$44.4M	Hold	1,400,000	–	–	0.38%	43
2014 Q3	$33.2M	Hold	1,400,000	–	–	0.26%	60
2014 Q2	$42M	Buy	+1,400,000	New	+$37.8M	0.31%	59

Other funds holding IPXL

Hound Partners New York $863M AUM 11.22% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Highfields Capital Management's IPXL Position: Q3 2015 in Review

Highfields Capital Management sold out of Impax Laboratories, Inc. (IPXL) in Q3 2015, closing a stake of 154,300 shares — an estimated $7.08M sold.

Highfields Capital Management first reported a position in IPXL in Q2 2014 and held it in 5 quarters. The position peaked at $65.6M in Q1 2015. 195 funds tracked by Wall St. Rank hold IPXL as of Q3 2015.

Highfields Capital Management reported no remaining Impax Laboratories, Inc. position as of Q3 2015 after selling out during the quarter.
Highfields Capital Management sold 154,300 Impax Laboratories, Inc. shares in Q3 2015, an estimated $7.08M.
Highfields Capital Management first reported a position in Impax Laboratories, Inc. in Q2 2014 and held it in 5 quarters.
Highfields Capital Management's Impax Laboratories, Inc. position peaked at $65.6M in Q1 2015.
195 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2015.

Based on Highfields Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.